Direct Biologics, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Oral Delivery of Therapeutic Mammalian Cells (US 11,707,489) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,707,489 | Oral Delivery of Therapeutic Mammalian Cells In force · Medium confidence | In force | Medium confidence | |
| US 12,570,980 | Methods and Compositions for Treating Inflammatory Conditions Associated with Infectious Disease In force · High confidence | In force | High confidence | |
| US 12,590,310 | Methods and Compositions for Treating Inflammatory Conditions Associated with Infectious Disease In force · High confidence | In force | High confidence | |
| US 12,213,995 | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use In force · From the USPTO record | In force | From the USPTO record | |
| US 12,453,743 | A Mesenchymal Stem Cell (MSC) Growgh Factor and Extracellular Vesicle Preparation in Frozen of Powdered Form and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,569,517 | Method for Treating Osteoarthritis with Mesenchymal Stem Cell Exosomes In force · High confidence | In force | High confidence | |
| US 12,502,407 | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending